281 related articles for article (PubMed ID: 33810942)
1. The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma.
Lee JH; Kim BK; Park SY; Tak WY; Park JY; Kim DY; Ahn SH; Sinn DH; Kim SU
Eur J Intern Med; 2021 Jul; 89():48-55. PubMed ID: 33810942
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.
Hu Z; Zeng H; Hou J; Wang J; Xu L; Zhang Y; Chen M; Zhou Z
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458386
[TBL] [Abstract][Full Text] [Related]
3. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
Wang XH; Hu ZL; Fu YZ; Hou JY; Li WX; Zhang YJ; Xu L; Zhou QF; Chen MS; Zhou ZG
J Gastroenterol; 2022 Mar; 57(3):185-198. PubMed ID: 35152312
[TBL] [Abstract][Full Text] [Related]
5. Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy.
Kao WY; Tan EC; Lee HL; Huang YH; Huo TI; Chang CC; Chiou JF; Hou MC; Wu JC; Su CW
Aliment Pharmacol Ther; 2023 Jun; 57(11):1299-1312. PubMed ID: 36914943
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
Choi J; Jo C; Lim YS
Hepatology; 2021 Feb; 73(2):661-673. PubMed ID: 32324905
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir versus entecavir on the prognosis of hepatitis B-related hepatocellular carcinoma after surgical resection: a randomised controlled trial.
Linye H; Zijing X; Xiaoyun Z; Zhihui L; Tianfu W; Chuan L
Int J Surg; 2023 Oct; 109(10):3032-3041. PubMed ID: 37335984
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: A systematic review and meta-analysis.
Giri S; Agrawal D; Afzalpurkar S; Gopan A; Angadi S; Sundaram S
J Viral Hepat; 2023 Feb; 30(2):108-115. PubMed ID: 36321967
[TBL] [Abstract][Full Text] [Related]
9. Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study.
Qi W; Shen J; Dai J; Wu Y; Zhang Y; Leng S; Gao F; Ran S; Peng W; Zhang X; Wen T; Li C
Cancer Med; 2021 Dec; 10(23):8421-8431. PubMed ID: 34643050
[TBL] [Abstract][Full Text] [Related]
10. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
[TBL] [Abstract][Full Text] [Related]
11. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
[TBL] [Abstract][Full Text] [Related]
12. Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals.
Cho H; Ahn H; Lee DH; Lee JH; Jung YJ; Chang Y; Nam JY; Cho YY; Lee DH; Cho EJ; Yu SJ; Lee JM; Kim YJ; Yoon JH
J Viral Hepat; 2018 Jun; 25(6):707-717. PubMed ID: 29316069
[TBL] [Abstract][Full Text] [Related]
13. Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea.
Choi H; Seo GH
J Korean Med Sci; 2021 Apr; 36(14):e89. PubMed ID: 33847080
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapy.
Chang KC; Su TH; Liao SH; Tseng TC; Huang SC; Hsu SJ; Hong CM; Liu CH; Yang HC; Liu CJ; Kao JH
J Formos Med Assoc; 2024 Feb; ():. PubMed ID: 38423922
[TBL] [Abstract][Full Text] [Related]
15. Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States.
Kim WR; Telep LE; Jump B; Lu M; Ramroth H; Flaherty J; Gaggar A; Chokkalingam AP; Gordon SC
Aliment Pharmacol Ther; 2022 Apr; 55(7):828-835. PubMed ID: 35137422
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
Ha I; Chung JW; Jang ES; Jeong SH; Kim JW
J Gastroenterol Hepatol; 2020 Oct; 35(10):1774-1781. PubMed ID: 32154938
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis.
Liu H; Han CL; Tian BW; Ding ZN; Yang YF; Ma YL; Yang CC; Meng GX; Xue JS; Wang DX; Dong ZR; Chen ZQ; Hong JG; Li T
Expert Rev Gastroenterol Hepatol; 2023; 17(6):623-633. PubMed ID: 37148261
[TBL] [Abstract][Full Text] [Related]
18. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.
Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
Hepatol Int; 2021 Oct; 15(5):1083-1092. PubMed ID: 34402025
[TBL] [Abstract][Full Text] [Related]
19. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
Su F; Berry K; Ioannou GN
Gut; 2021 Feb; 70(2):370-378. PubMed ID: 32229544
[TBL] [Abstract][Full Text] [Related]
20. The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial.
Peng W; Yi M; Qi X; Qi W; Li C; Wen T
Trials; 2023 Dec; 24(1):781. PubMed ID: 38042834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
